H.R. No. 1495 is a resolution from the Texas House of Representatives aimed at suspending certain legislative rules to assist a conference committee in reconciling differences in Senate Bill 2308. This bill proposes the establishment of a consortium to conduct clinical trials for ibogaine, a substance being considered for the treatment of opioid use disorder and other related conditions. The resolution allows the committee to make necessary amendments, such as updating definitions and clarifying the roles of various entities involved in the drug development process, while streamlining the selection process for the consortium by removing outdated provisions.

The resolution also sets forth a framework for conducting clinical trials under Chapter 491 of the Health and Safety Code, specifically for ibogaine. It requires the Health and Human Services Commission (HHSC) to ensure that selected consortia have secured matching funds from non-state sources before any state funds are allocated. Additionally, it mandates that only institutions of higher education or hospitals can serve as trial sites and that consortium members must submit an investigational new drug application to the FDA. Reporting requirements are established for the consortia, including quarterly updates to the HHSC and annual reports to the legislature, while also ensuring that revenue generated from intellectual property rights benefits the state and programs for veterans. The HHSC is tasked with accepting proposals from consortia within 60 days of the resolution's effective date, expediting the drug development process.